Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 8, Number 4—April 2002
Research

Laboratory Reporting of Staphylococcus aureus with Reduced Susceptibility to Vancomycin in United States Department of Veterans Affairs Facilities1

Stephen M. Kralovic*†‡Comments to Author , Linda H. Danko*†, and Gary A. Roselle*†‡
Author affiliations: *Department of Veterans Affairs Central Office, Washington, D.C., USA; †Cincinnati Veterans Affairs Medical Center, Cincinnati, Ohio, USA; ‡University of Cincinnati College of Medicine, Cincinnati, Ohio, USA

Main Article

Table 2

Susceptibility to selected gram-positive agents of isolates of reported Staphylococcus aureus with reduced susceptibility to vancomycin from United States Veterans Health Administration medical facilities, FFY 1999a

Case Beta-lactamase MIS/sensitivity status
oxacillin imipenem rifampin TMP/SMX erythromycin TCN clindamycin chloramphenicol
1 negative /R /S /R /S /R
2 positive <0.5 μg/mL <4 μg/mL <1 μg/mL <2 μg/mL =0.5 μg/mL <2 μg/mL <0.25 μg/mL
3 positive >2 μg/mL >8 μg/mL/R <1 μg/mL <2 μg/mL >4 μg/mL/R <2 μg/mL >2 μg/mL/R
4 positive >4 μg/mL >8 μg/mL/R <1 μg/mL <2 μg/mL >4 μg/mL/R <2 μg/mL >2 μg/mL/R
5 positive <0.5 μg/mL/S >8 μg/mL/R >2 μg/mL/R <2/38 μg/mL/S >8 μg/mL/R >2 μg/mL/R
6 positive >2 μg/mL/R 2 μg/mL/R >1 μg/mL/S <2/38 μg/mL/S >4 μg.mL/R <2 μg/mL/S 8 μg/mL/S
7 positive >2 μg/mL/R >8 μg/mL/R >2 μg/mL/R >2/38 μg/mL/R >4 μg/mL/R >8 μg/mL/R 16 μg/mL/I
8 positive >2 μg/mL/R >8 μg/mL/R >1 μg/mL/S <2/38 μg/mL/S >4 μg/mL/R <2 μg/mL/S >2 μg/mL/R 16 μg/mL/I
9 positive >2 μg/mL/R <1 μg/mL/S <2 μg/mL/S >4 μg/mL/R <2 μg/mL/S >2 μg/mL/R
10 negative <0.5 μg/mL/S <1 μg/mL/S <2 μg/mL/S <0.25 μg/mL/S <2 μg/mL/S =0.5 μg/mL/S
11 positive <0.5 μg/mL/S <1 μg/mL/S <2 μg/mL/S >4 μg/mL/R <2 μg/mL/S <0.25 μg/mL/S
12 positive >2 μg/mL/R <1 μg/mL/S <2 μg/mL/S >4 μg/mL/R <2 μg/mL/S >2 μg/mL/R
13 positive <0.5 μg/mL/S <1 μg/mL/S <2 μg/mL/S >4 μg/mL/R >8 μg/mL/R >2 μg/mL/R
14 positive >2 μg/mL/R >2 μg/mL/R <2 μg/mL/S >4 μg/mL/R <2 μg/mL/S >2 μg/mL/R
15 /R <2 μg/mL/S /R <2 μg/mL/S <2 μg/mL/S =8 μg/mL/S
16 1 μg/mL/S <2/38 μg/mL/S 0.5 μg/mL/S >2 μg/mL/R
17 >4 μg/mL/R <2/38 μg/mL/S >4 μg/mL/R >2 μg/mL/R
18 positive <0.05 μg/mL <4 μg/mL <1 μg/mL <2 μg/mL <0.25 μg/mL <2 μg/mL 0.5 μg/mL
19 positive >8 μg/mL/R >4 μg/mL/R <16 μg/mL/S >8 μg/mL/R >16 μg/mL/R >8 μg/mL/R
Totalb 14/16=pos 12/19 =R 6/8=R 4/15=R 1/19=R 14/18=R 4/17=R 12/17=R 0/4=R

aFFY=Federal fiscal year; S=susceptible, I=intermediate and R=resistant based on laboratory interpretative criteria.
bThe authors took the liberty of placing interpretation on some reported MIC values that did not have an interpretation of S, I, or R on information provided from the facility.

Main Article

1A portion of this material was presented at the 11th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America in Toronto, Ontario, Canada (Abstract #49), April 2001.

Page created: July 15, 2010
Page updated: July 15, 2010
Page reviewed: July 15, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external